BR112023019757A2 - Proteína de fusão imunogênica - Google Patents
Proteína de fusão imunogênicaInfo
- Publication number
- BR112023019757A2 BR112023019757A2 BR112023019757A BR112023019757A BR112023019757A2 BR 112023019757 A2 BR112023019757 A2 BR 112023019757A2 BR 112023019757 A BR112023019757 A BR 112023019757A BR 112023019757 A BR112023019757 A BR 112023019757A BR 112023019757 A2 BR112023019757 A2 BR 112023019757A2
- Authority
- BR
- Brazil
- Prior art keywords
- amino acid
- amino acids
- acid sequence
- fusion protein
- immunogenic fusion
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title abstract 5
- 230000002163 immunogen Effects 0.000 title abstract 5
- 150000001413 amino acids Chemical class 0.000 abstract 8
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 7
- 102000037865 fusion proteins Human genes 0.000 abstract 4
- 206010061372 Streptococcal infection Diseases 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21165674.9A EP4066854A1 (en) | 2021-03-29 | 2021-03-29 | Immunogenic fusion protein |
| PCT/EP2022/058309 WO2022207657A1 (en) | 2021-03-29 | 2022-03-29 | Immunogenic fusion protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023019757A2 true BR112023019757A2 (pt) | 2023-10-31 |
Family
ID=75277909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023019757A BR112023019757A2 (pt) | 2021-03-29 | 2022-03-29 | Proteína de fusão imunogênica |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240173394A1 (https=) |
| EP (2) | EP4066854A1 (https=) |
| JP (1) | JP2024512722A (https=) |
| KR (1) | KR20230163500A (https=) |
| CN (1) | CN117120081A (https=) |
| AU (1) | AU2022248869A1 (https=) |
| BR (1) | BR112023019757A2 (https=) |
| CA (1) | CA3212987A1 (https=) |
| IL (1) | IL307256A (https=) |
| MX (1) | MX2023011502A (https=) |
| WO (1) | WO2022207657A1 (https=) |
| ZA (1) | ZA202309225B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4553166A1 (en) | 2023-11-07 | 2025-05-14 | MinervaX ApS | Method for preparing a sample for analysis |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL107458A0 (en) | 1992-11-02 | 1994-02-27 | Gen Hospital Corp | Conjugate vaccine against group b streptococcus |
| HU217582B (hu) | 1993-03-19 | 2000-02-28 | Gunnar Lindahl | Streptococcus B csoportba tartozó törzsek elleni immunitást biztosító, Rib fehérjenevű felületi protein, eljárás a protein tisztítására, reagenskészlet és gyógyszerkészítmény |
| US6426074B1 (en) | 1997-03-19 | 2002-07-30 | The Brigham And Women's Hospital Inc. | Group B Streptococcus vaccine |
| SI2144924T1 (sl) * | 2007-04-16 | 2016-12-30 | Minervax Aps | Cepivo s fuzijskimi beljakovinami |
| CN108135992A (zh) * | 2015-10-21 | 2018-06-08 | 米纳瓦克斯有限责任公司 | 免疫原性融合蛋白 |
| US10888610B2 (en) * | 2015-12-30 | 2021-01-12 | Minerv Ax Aps | Immunogenic complex for eliciting protective immunity against group b streptococcus |
-
2021
- 2021-03-29 EP EP21165674.9A patent/EP4066854A1/en not_active Withdrawn
-
2022
- 2022-03-29 JP JP2023560549A patent/JP2024512722A/ja active Pending
- 2022-03-29 CN CN202280027427.3A patent/CN117120081A/zh active Pending
- 2022-03-29 BR BR112023019757A patent/BR112023019757A2/pt unknown
- 2022-03-29 KR KR1020237037124A patent/KR20230163500A/ko active Pending
- 2022-03-29 WO PCT/EP2022/058309 patent/WO2022207657A1/en not_active Ceased
- 2022-03-29 US US18/284,513 patent/US20240173394A1/en active Pending
- 2022-03-29 AU AU2022248869A patent/AU2022248869A1/en active Pending
- 2022-03-29 MX MX2023011502A patent/MX2023011502A/es unknown
- 2022-03-29 EP EP22713429.3A patent/EP4313134A1/en active Pending
- 2022-03-29 CA CA3212987A patent/CA3212987A1/en active Pending
- 2022-03-29 IL IL307256A patent/IL307256A/en unknown
-
2023
- 2023-10-02 ZA ZA2023/09225A patent/ZA202309225B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4313134A1 (en) | 2024-02-07 |
| MX2023011502A (es) | 2023-10-19 |
| CA3212987A1 (en) | 2022-10-06 |
| AU2022248869A9 (en) | 2023-11-09 |
| US20240173394A1 (en) | 2024-05-30 |
| JP2024512722A (ja) | 2024-03-19 |
| AU2022248869A1 (en) | 2023-10-26 |
| KR20230163500A (ko) | 2023-11-30 |
| EP4066854A1 (en) | 2022-10-05 |
| IL307256A (en) | 2023-11-01 |
| ZA202309225B (en) | 2025-03-26 |
| CN117120081A (zh) | 2023-11-24 |
| WO2022207657A1 (en) | 2022-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lory et al. | Expression of enzymic activity by exotoxin A from Pseudomonas aeruginosa | |
| AU708856B2 (en) | Peptide fragment of the respiratory syncytial virus protein g, immunogenic agent, pharmaceutical composition containing it and preparation process | |
| Cordwell et al. | Identification of membrane‐associated proteins from Campylobacter jejuni strains using complementary proteomics technologies | |
| Moreno‐Brito et al. | A Trichomonas vaginalis 120 kDa protein with identity to hydrogenosome pyruvate: ferredoxin oxidoreductase is a surface adhesin induced by iron | |
| PE20231439A1 (es) | Proteinas f de hmpv estabilizadas por prefusion | |
| NZ561042A (en) | Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli - SEQ ID: 7052 | |
| Miyazaki et al. | Clostridium botulinum type D toxin: purification, molecular structure, and some immunological properties | |
| US20140194346A1 (en) | Pasteurellaceae vaccines | |
| BR0015137A (pt) | Peptìdeos antigênicos de neisseria | |
| BR112023019757A2 (pt) | Proteína de fusão imunogênica | |
| BR9803960A (pt) | Gene de desidrogenase de d-sorbitol. | |
| BR9802361A (pt) | Derivado imunogênico detoxificado de b-toxina de clostridium perfringens ou um seu fragmento imunogênico, sequência de nucleotìdeos compreendendo um fragmento de dna mutante, bactéria clostriduim perfringensm sistema de expressão baseado em uma bactéria gram-positiva, vacina para combater infecção de clostridium perfrigens, processo para a preparação de b-toxina nativa de clostridium perfrigens, e, processo para preparação de uma vacina para combater infecção de clostridium perfrigens. | |
| Owen et al. | Identification and partial characterization of a novel bipartite protein antigen associated with the outer membrane of Escherichia coli | |
| Ionas et al. | A study of the heterogeneity of isolates of Mycoplasma ovipneumoniae from sheep in New Zealand | |
| Jan et al. | Acylation and immunological properties of Mycoplasma gallisepticum membrane proteins | |
| BR0205083A (pt) | Polipeptìdeo isolado, composição farmacêutica, proteìna de fusão, polinucleotìdeo isolado, vetor de expressão, célula hospedeira recombinante e métodos de produzir um polipeptìdeo, de detectar a presença da expressão de gene em uma amostra biológica, de expandir células monocìticas ou progenitores de células de monócitos e de estimular uma resposta imune em um mamìfero exposto a um antìgeno ou patógeno | |
| BR0210853A (pt) | ácidos nucléicos que codificam um antìgeno de 56 e 82 kda recombinantes de gametócitos de eimeria máxima e seus usos | |
| Setlow et al. | Localization of low-molecular-weight basic proteins in Bacillus megaterium spores by cross-linking with ultraviolet light | |
| Singh et al. | Molecular heterogeneity of plpE gene in Indian isolates of Pasteurella multocida and expression of recombinant PlpE in vaccine strain of P. multocida serotype B: 2 | |
| Altmann et al. | A new method for the extraction and purification of K99 pili from enterotoxigenic Escherichia coli and their characterization | |
| Tatum et al. | Protection against fowl cholera conferred by vaccination with recombinant Pasteurella multocida filamentous hemagglutinin peptides | |
| US8709437B2 (en) | Clostridium chauvoei polypeptide, DNA encoding the polypeptide and a vaccine comprising the polypeptide | |
| BR112021008137A2 (pt) | Sensor | |
| Talluri et al. | CagL from Helicobacter pylori has ADP-ribosylation activity and exerts partial protective efficacy in mice | |
| Iwanaga et al. | Pili of Vibrio cholerae widely distributed in serogroup O1 strains |